CELZ News & Events

Creative Medical Technology announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5M, before deducting financial advisory fees. Roth Capital Partners is acting as the company's financial advisor for this transaction. In consideration for the immediate exercise of the existing warrants for cash, the company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date. The transaction is expected to close on June 30, 2026. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Stock futures were broadly higher following a mixed session as traders continue to question whether the AI trade was losing momentum, though the latest chip demand signals are pushing the narrative back toward continued infrastructure expansion.Meanwhile, The Wall Street Journal reported that Iran has attacked a Singapore-flagged cargo ship traveling through the Strait of Hormuz. The attack inflicted damage on the ship's bridge but left no casualties, according to U.K. Maritime Trade Operations.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Titan Miningup 61.4% after it was selected by the U.S. Army for a domestic minerals processing partnershipGates Industrialup 2.3% after its shareholders approved its redomiciliation to BermudaLOWER -Creative Medicaldown 22% after filing to sell 3.05M shares of common stock

Creative Medical files to sell 3.05M shares of common stock

Creative Medical announced that the FDA has cleared an expansion of the company's FDA-cleared ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative disc disease. Under the amended protocol, the Company is enrolling an additional 15 patients receiving less than 90 mg per day in morphine equivalents to further characterize safety and efficacy in patients with ongoing opioid use associated with the treatment of chronic lower back pain. The new cohort is already more than 85% enrolled and leverages the Company's newly implemented, patient-centric AI pain medication monitoring system.